GLP-1 Receptor Agonists and Supplements: Supplements to Take or Avoid When Using a GLP-1 Drug (2024

GLP-1 Receptor Agonists and Supplements: Supplements to Take or Avoid When Using a GLP-1 Drug (2024–2026 Review)

By Editorial Team - April 03, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for type 2 diabetes, have rapidly expanded into obesity management and are now being explored across multiple therapeutic domains. Recent studies (2024–2026) suggest potential benefits in dermatologic diseases, neuroinflammatory conditions, metabolic dysfunction, and systemic inflammation. In parallel, emerging clinical guidance highlights the importance of nutritional status, targeted supplementation, and safety considerations—including concerns around compounded formulations. This review synthesizes current evidence and practical considerations for optimizing outcomes.

1. Introduction

GLP-1 receptor agonists—including semaglutide, liraglutide, and tirzepatide—have transformed the management of obesity and type 2 diabetes. Their mechanisms extend beyond glucose regulation to include:

Appetite suppression
Delayed gastric emptying
Anti-inflammatory effects
Modulation of insulin sensitivity

As clinical use expands, attention is increasingly turning to nutritional adequacy, supplementation strategies, and formulation safety.

2. Mechanisms of Action: A Multi-System Perspective

2.1 Metabolic Regulation

GLP-1 RAs improve glycemic control by enhancing insulin secretion and reducing glucagon levels (Lee, 2006; Tran, 2017).

2.2 Anti-Inflammatory Effects

Emerging studies (Araj-Khodaei 2024; Johnson 2025) demonstrate:

Reduction in pro-inflammatory cytokines
Improved endothelial function
Decreased oxidative stress

2.3 Gastrointestinal Effects and Nutrient Intake

GLP-1 RAs slow gastric emptying and reduce appetite, which may lead to:

Reduced caloric intake
Lower protein consumption
Potential micronutrient insufficiency

3. Clinical Applications Beyond Diabetes and Obesity

3.1 Obesity and Metabolic Disease

(Butsch 2025; Kanai 2024; Urbina 2026)

Sustained weight loss (10–20%)
Improved metabolic markers
Reduced cardiovascular risk

3.2 Dermatologic Conditions

(Kang 2024; Vidal 2026; Branyiczky 2025; Xu 2026)

Psoriasis improvement
Reduced hidradenitis suppurativa flares
Benefits in metabolic skin disorders

3.3 Neurological and Autoimmune Disorders

(Balshi 2025; Araj-Khodaei 2024)

Potential reduction in neuroinflammation
Early signals in multiple sclerosis

3.4 Cardiometabolic Effects

(Mehta 2025; White 2026; Liang 2022; Melis 2025)

Cardiovascular event reduction
Improved insulin resistance and NAFLD

4. Nutritional Considerations and Supplementation with GLP-1 Therapy

4.1 Key Principle

Certain supplements may be helpful when taking a GLP-1 drug, but others should be used with caution or avoided, and it may be important to monitor levels of particular vitamins and minerals.

4.2 Common Nutritional Risks

Protein deficiency → lean mass loss
Vitamin B12 deficiency
Iron deficiency
Electrolyte imbalance

4.3 Potentially Helpful Supplements

Protein supplementation → preserves muscle mass
Multivitamin → covers dietary gaps
Vitamin B12 → supports neurologic function
Vitamin D → metabolic and immune support
Electrolytes → for GI side effects

4.4 Supplements and Formulations to Use with Caution

Fat-soluble vitamins (A, D, E, K) → accumulation risk
Herbal appetite suppressants → excessive caloric restriction
Glucose-lowering supplements (e.g., berberine) → additive effects

⚠️ Compounded GLP-1 + Vitamin B12: Emerging Safety Signal

A recent study (24) raises red flags about compounded tirzepatide mixed with vitamin B-12—a formulation increasingly marketed for weight loss.

Tirzepatide is the active ingredient in
- Zepbound
- Mounjaro

Key concerns highlighted:

Lack of standardization in compounded formulations
Potential stability issues when mixed with vitamin B12
Unknown pharmacokinetics and dosing consistency
Limited regulatory oversight compared to approved products

Clinical implications:

Patients should prefer FDA/EMA-approved formulations when available
Avoid assuming compounded versions are equivalent
Use caution with “enhanced” or “custom-mixed” GLP-1 products marketed online

4.5 Clinical Monitoring Recommendations

Consider periodic monitoring of:

Vitamin B12
Iron studies
Vitamin D
Electrolytes
Body composition (lean vs fat mass)

5. Safety Profile and Adverse Effects

Common

Nausea
Vomiting
GI discomfort

Less Common

Gallbladder disease
Pancreatitis (rare)

Long-Term Safety

Generally favorable, but ongoing monitoring required (Mehrtash 2025; White 2026).

6. Limitations of Current Evidence

Many non-metabolic uses are observational
Limited RCTs in dermatology and neurology
Sparse data on nutrition and compounded formulations

7. Clinical Implications

For Physicians

Integrate nutritional and supplement review into GLP-1 care
Be cautious with compounded formulations
Monitor for micronutrient deficiencies

For Patients

Focus on protein intake and balanced nutrition
Avoid unverified compounded GLP-1 products
Seek medical advice before combining supplements

8. Future Directions

Trials on GLP-1 + nutrition optimization
Research on formulation stability and compounding safety
Precision medicine approaches

9. Conclusion

GLP-1 receptor agonists are evolving into multi-system therapies with broad clinical potential. However, their appetite-suppressing effects—and the rise of compounded formulations—introduce new considerations.

A comprehensive strategy combining evidence-based pharmacotherapy, nutritional optimization, and caution around non-standard formulations is essential to maximize benefits while minimizing risks.

Search This Blog

The Medical Advisor